Group 1 - Company Baijin Life Sciences (01466) has signed a strategic cooperation framework agreement with Youhuan (Suzhou) Biopharmaceutical Technology Co., Ltd. to invest in Youhuan through equity acquisition, aiming to establish a leading global circRNA technology research and development platform [1] - The agreement is set to expire on December 31, 2026, and either party can terminate the agreement with a 10-day notice [1] Group 2 - Youhuan is a biopharmaceutical company focused on circRNA technology platform development and innovative drug development, also providing CRO services [2] - Youhuan has successfully obtained U.S. patent authorization for "Circular RNAs and Preparation Methods thereof" and Chinese invention patent authorization for "A Residue-Free Sequence Circular RNA Based on Ribozyme Self-Splicing and Its Preparation Method" [2] - The company is engaged in deep cooperation with large enterprises in the international drug development field and has signed contracts in certain cell application areas with a global multinational company [2] Group 3 - The initial focus of the collaboration will include exploring long-acting, stable expression of cytokines and enzymes for treating liver metabolic diseases [3] - Research will also target circRNA and exosome drug delivery technologies, developing new delivery systems based on exosome and cell platforms [3] - The development of engineered exosome drugs and cell drugs for cardiovascular and tissue repair applications, as well as treatments for neurodegenerative diseases like Alzheimer's and Parkinson's, is also a priority [3] - The collaboration aims to develop precise, efficient, and safe cell reprogramming and differentiation technologies for genetic disease treatment [3]
佰金生命科学(01466)附属拟入股投资优环生物 打造全球领先的环状RNA(circ RNA)技术研发平台